Bristol-Myers Squibb (NYSE:BMY) Given Average Rating of “Hold” by Analysts

Shares of Bristol-Myers Squibb (NYSE:BMYGet Free Report) have received a consensus recommendation of “Hold” from the nineteen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, fifteen have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $60.00.

BMY has been the subject of a number of recent analyst reports. Barclays decreased their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th.

View Our Latest Analysis on BMY

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Milestone Investment Advisors LLC acquired a new stake in Bristol-Myers Squibb in the 3rd quarter worth about $27,000. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth about $27,000. ESL Trust Services LLC purchased a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Accordant Advisory Group Inc purchased a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $31,000. Finally, Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $34,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 2.1 %

Shares of Bristol-Myers Squibb stock opened at $41.09 on Tuesday. Bristol-Myers Squibb has a 12 month low of $39.91 and a 12 month high of $66.46. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a market cap of $83.29 billion, a PE ratio of -13.25, a price-to-earnings-growth ratio of 13.63 and a beta of 0.45. The business has a fifty day simple moving average of $46.69 and a 200 day simple moving average of $49.29.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.05 earnings per share. Research analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

About Bristol-Myers Squibb

(Get Free Report

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.